MedCap AB (publ)
MedCap AB (publ) provides investment management and fund operator services within the financial sector, generating revenue primarily through asset management fees and related financial services.
Business. MedCap AB (publ) is an investment management and fund operator headquartered in Sweden, operating within the Banking & Investment Services sector. The company generates revenue primarily through fee-based models associated with managing assets under management. It is listed on the Nasdaq Stockholm exchange under the ticker symbol MEDCAP.ST. Specific details regarding operating segments or geographic breakdowns are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
MedCap AB (publ) is an investment management and fund operator headquartered in Sweden, operating within the Banking & Investment Services sector. The company generates revenue primarily through fee-based models associated with managing assets under management. It is listed on the Nasdaq Stockholm exchange under the ticker symbol MEDCAP.ST. Specific details regarding operating segments or geographic breakdowns are not available.
MedCap maintains a strong liquidity position, with a current ratio of 2.01 and cash and equivalents of 370.4 million SEK, which supports its short-term obligations. However, the company's net cash position is negative after subtracting total debt, indicating potential liquidity constraints in the medium term.
The company's profitability is reflected in a return on equity (ROE) of 15.14% and a return on assets (ROA) of 8.43%, both of which are strong indicators of efficient capital use and asset management. These metrics suggest that MedCap is performing well relative to its equity and asset base.
Geographically and segment-wise, MedCap's revenue is concentrated in its core investment management and fund operations, with no disclosed diversification into other business lines or regions. This concentration may expose the company to sector-specific risks, particularly in the financial services industry.
Looking ahead, MedCap is projected to maintain a stable growth trajectory, with no significant revenue deltas expected in the current or next fiscal year. The company's operating cash flow of 342.7 million SEK and free cash flow of 311.8 million SEK support this outlook, although capital expenditures are negative, indicating asset disposals or reductions in capital spending.
Risk factors for MedCap include medium liquidity risk and a negative net cash position after debt. The company's dilution potential is low, and no adjustments have been applied to its valuation metrics. However, the risk assessment highlights the need for continued monitoring of its debt and liquidity positions.
Recent events and filings have not disclosed any material changes in the company's operations or strategic direction. Analysts have provided a mean price target of 617.50 SEK, with a median of 617.50 SEK, and a mean recommendation of 2.00, indicating a generally positive outlook from the investment community.
- MedCap has a strong ROE of 15.14% and ROA of 8.43%, indicating efficient capital and asset use.
- The company's liquidity is supported by a current ratio of 2.01 and 370.4 million SEK in cash and equivalents.
- MedCap's revenue is concentrated in its core investment management and fund operations, with no disclosed diversification.
- Analysts have provided a positive outlook, with a mean price target of 617.50 SEK and a mean recommendation of 2.00.
- The company's net cash position is negative after subtracting total debt, indicating potential liquidity constraints.
- MedCap is projected to maintain a stable growth trajectory with no significant revenue deltas expected in the current or next fiscal year.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 19,24 |
| Revenue | —no estimate | —no estimate | 2,4B SEK |
| Operating income | —no estimate | —no estimate | 381,0M SEK |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- MedCap AB (publ) Market data — financials · 2026-05-28
- MedCap AB (publ) Market data — analyst estimates · 2026-05-28